Biotech · Public company · San Diego, CA, US
Artiva Biotherapeutics, Inc.
Ticker ARTV · SEC CIK 0001817241
Track this companyFree. Adds Artiva Biotherapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials63 recruiting or active
Pipeline programs15From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline15
- AB-101Phase 2 · Non Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- AB-201Phase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- Allogeneic NK CellsPhase 2 · Refractory Rheumatoid Arthritis (RA)ClinicalTrials.gov · fetched Nov 12, 2026
- BendamustinePhase 2 · Non Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 2 · Non Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- FludarabinePhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- FludarabinePhase 2 · Non Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- Interleukin-2Phase 2 · Non Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- RituximabPhase 2 · Non Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- AB-101Phase 1 · Lupus Nephritis - WHO Class IIIClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 1 · Lupus Nephritis - WHO Class IIIClinicalTrials.gov · fetched Nov 12, 2026
- FludarabinePhase 1 · Lupus Nephritis - WHO Class IIIClinicalTrials.gov · fetched Nov 12, 2026
- ObinutuzumabPhase 1 · Lupus Nephritis - WHO Class IIIClinicalTrials.gov · fetched Nov 12, 2026
- RituximabPhase 1 · Lupus Nephritis - WHO Class IIIClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.PHASE2 · RECRUITING · started Jul 9, 2025ClinicalTrials.gov NCT06991114 · fetched Nov 12, 2026
- Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.PHASE1 · RECRUITING · started May 15, 2024ClinicalTrials.gov NCT06581562 · fetched Nov 12, 2026
- AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus ErythematosusPHASE1 · ACTIVE_NOT_RECRUITING · started Apr 3, 2024ClinicalTrials.gov NCT06265220 · fetched Nov 12, 2026
- Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCLPHASE2 · TERMINATED · started Oct 10, 2023ClinicalTrials.gov NCT05883449 · fetched Nov 12, 2026
- A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid TumorsPHASE1_PHASE2 · WITHDRAWN · started Aug 1, 2023ClinicalTrials.gov NCT05678205 · fetched Nov 12, 2026
- AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin LymphomaPHASE1_PHASE2 · COMPLETED · started Mar 29, 2021ClinicalTrials.gov NCT04673617 · fetched Nov 12, 2026
SEC filings12
- 8-K/A · 8-K/ASEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 27, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 11, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 22, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 19, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 8, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 8, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 8, 2026 · fetched Nov 12, 2026
- 10-K/A · 10-K/ASEC EDGAR · filed Apr 30, 2026 · fetched Nov 12, 2026